Pregnancy and Neonatal Outcomes Following Prenatal Exposure to Dolutegravir: Findings From the Antiretroviral Pregnancy Registry.

BACKGROUND: Safe and effective antiretrovirals (ARVs) are essential for managing HIV-1 in pregnant individuals and ensuring positive pregnancy outcomes. International guidelines recommend dolutegravir-based regimens as the preferred option for pregnant individuals or those planning to conceive. SETTING: The Antiretroviral Pregnancy Registry (APR) is a voluntary, international, prospective, exposure-registration cohort study providing early warning signals of major teratogenicity with ARV use. METHODS: Pregnancy and neonatal outcomes following prenatal dolutegravir exposure were assessed among prospectively reported pregnancies starting in 2013, after dolutegravir approval for HIV-1 treatment, through January 31, 2025. Birth defect prevalence after first-trimester dolutegravir exposure was compared with prevalence during the second and third trimesters, for other ARVs, and the general US population. RESULTS: Among 2075 pregnancies exposed to dolutegravir, initial exposure occurred during periconception, later first trimester, second trimester, and third trimester in 53%, 14%, 24%, and 9% of pregnancies, respectively. Overall, 93% (1970/2127) of pregnancy outcomes resulted in live births. Birth defect prevalence after first-trimester dolutegravir exposure was 3.3% (95% CI, 2.4%-4.4%), which was comparable to rates for other ARVs and the general US population. A single neural tube defect (anencephaly) was reported among pregnancies with earliest dolutegravir exposure during periconception, corresponding to a prevalence of 0.1% (1/1120). Among the 1802 singleton live births without defects, 89% (n=1605) were delivered at ≥37 weeks of gestation, and 85% (n=1540) had a birth weight ≥2500 g. CONCLUSION: Findings confirm the safety of prenatal dolutegravir exposure and reinforce dolutegravir-based regimens as safe options for all people of childbearing potential.

Authors

Institutions

Publication Details

Journal
UNC Libraries
Published
2026-11-18
DOI
https://doi.org/10.17615/58j9-e482
Primary Topic
HIV/AIDS drug development and treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pregnancy and Neonatal Outcomes Following Prenatal Exposure to Dolutegravir: Findings From the Antiretroviral Pregnancy Registry.

Michelle Kisare, William R. Short, Karen Beckerman, Hugh H. Tilson et al.
UNC Libraries
HIV/AIDS drug development and treatment
article

Pregnancy and Neonatal Outcomes Following Prenatal Exposure to Dolutegravir: Findings From the Antiretroviral Pregnancy Registry.

Michelle Kisare, William R. Short, Karen Beckerman, Hugh H. Tilson, Vani X. Vannappagari, Angela E. Scheuerle, Jessica D. Albano, Lynne Mofenson, Claire Thorne, Leigh Ragone, Nicole Carneal-Frazer, Taylor Cook, Annemiek de Ruiter
article en

Abstract

BACKGROUND: Safe and effective antiretrovirals (ARVs) are essential for managing HIV-1 in pregnant individuals and ensuring positive pregnancy outcomes. International guidelines recommend dolutegravir-based regimens as the preferred option for pregnant individuals or those planning to conceive. SETTING: The Antiretroviral Pregnancy Registry (APR) is a voluntary, international, prospective, exposure-registration cohort study providing early warning signals of major teratogenicity with ARV use. METHODS: Pregnancy and neonatal outcomes following prenatal dolutegravir exposure were assessed among prospectively reported pregnancies starting in 2013, after dolutegravir approval for HIV-1 treatment, through January 31, 2025. Birth defect prevalence after first-trimester dolutegravir exposure was compared with prevalence during the second and third trimesters, for other ARVs, and the general US population. RESULTS: Among 2075 pregnancies exposed to dolutegravir, initial exposure occurred during periconception, later first trimester, second trimester, and third trimester in 53%, 14%, 24%, and 9% of pregnancies, respectively. Overall, 93% (1970/2127) of pregnancy outcomes resulted in live births. Birth defect prevalence after first-trimester dolutegravir exposure was 3.3% (95% CI, 2.4%-4.4%), which was comparable to rates for other ARVs and the general US population. A single neural tube defect (anencephaly) was reported among pregnancies with earliest dolutegravir exposure during periconception, corresponding to a prevalence of 0.1% (1/1120). Among the 1802 singleton live births without defects, 89% (n=1605) were delivered at ≥37 weeks of gestation, and 85% (n=1540) had a birth weight ≥2500 g. CONCLUSION: Findings confirm the safety of prenatal dolutegravir exposure and reinforce dolutegravir-based regimens as safe options for all people of childbearing potential.

UNC Libraries
University of North Carolina at Chapel Hill (US)
Good health and well-being
HIV/AIDS drug development and treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon